The absence of any licensed hantavirus vaccine, combined with extended clinical development timelines, underpins the market's strong 94.5% implied probability against availability in 2026. As of mid-2026, candidates remain in preclinical or early-phase testing following advances like structural mapping and mRNA approaches, with no Phase 3 efficacy trials underway to meet regulatory standards for approval. A May 2026 Andes virus outbreak on a cruise ship highlighted the disease's severity and spurred research interest, yet historical patterns show vaccine licensing requires years beyond initial lab progress. Traders' consensus aligns with official surveillance data showing low case volumes and no accelerated emergency pathways sufficient for this calendar year, though unexpected regulatory fast-tracking or breakthrough trial results could still alter trajectories before year-end.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% вероятность
$129,605 Объем
$129,605 Объем
31 дек. 2026 г.
6% вероятность
$129,605 Объем
$129,605 Объем
31 дек. 2026 г.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The absence of any licensed hantavirus vaccine, combined with extended clinical development timelines, underpins the market's strong 94.5% implied probability against availability in 2026. As of mid-2026, candidates remain in preclinical or early-phase testing following advances like structural mapping and mRNA approaches, with no Phase 3 efficacy trials underway to meet regulatory standards for approval. A May 2026 Andes virus outbreak on a cruise ship highlighted the disease's severity and spurred research interest, yet historical patterns show vaccine licensing requires years beyond initial lab progress. Traders' consensus aligns with official surveillance data showing low case volumes and no accelerated emergency pathways sufficient for this calendar year, though unexpected regulatory fast-tracking or breakthrough trial results could still alter trajectories before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Открытие рынка: May 4, 2026, 10:39 AM ET
Объем
$129,605Дата окончания
31 дек. 2026 г.Открытие рынка
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The absence of any licensed hantavirus vaccine, combined with extended clinical development timelines, underpins the market's strong 94.5% implied probability against availability in 2026. As of mid-2026, candidates remain in preclinical or early-phase testing following advances like structural mapping and mRNA approaches, with no Phase 3 efficacy trials underway to meet regulatory standards for approval. A May 2026 Andes virus outbreak on a cruise ship highlighted the disease's severity and spurred research interest, yet historical patterns show vaccine licensing requires years beyond initial lab progress. Traders' consensus aligns with official surveillance data showing low case volumes and no accelerated emergency pathways sufficient for this calendar year, though unexpected regulatory fast-tracking or breakthrough trial results could still alter trajectories before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Объем
$129,605Дата окончания
31 дек. 2026 г.Открытие рынка
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...The absence of any licensed hantavirus vaccine, combined with extended clinical development timelines, underpins the market's strong 94.5% implied probability against availability in 2026. As of mid-2026, candidates remain in preclinical or early-phase testing following advances like structural mapping and mRNA approaches, with no Phase 3 efficacy trials underway to meet regulatory standards for approval. A May 2026 Andes virus outbreak on a cruise ship highlighted the disease's severity and spurred research interest, yet historical patterns show vaccine licensing requires years beyond initial lab progress. Traders' consensus aligns with official surveillance data showing low case volumes and no accelerated emergency pathways sufficient for this calendar year, though unexpected regulatory fast-tracking or breakthrough trial results could still alter trajectories before year-end.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы